Discover and read the best of Twitter Threads about #GEA
Most recents (10)
😳🤯The hour flew by & none of us noticed!!
🙏🏽 @FogacciJoao for bringing the 🇧🇷 flair to #TumorBoardTuesday & #GastricCancer!!
🏆Remember your🆓CME
Look for Case Wrap Up🎀 04/28/22
📅Mark your calendar for 05/10/22 8pm ET when @FlavioRochaMD joins our #VirtualTumorBoard!!
🙏🏽 @FogacciJoao for bringing the 🇧🇷 flair to #TumorBoardTuesday & #GastricCancer!!
🏆Remember your🆓CME
Look for Case Wrap Up🎀 04/28/22
📅Mark your calendar for 05/10/22 8pm ET when @FlavioRochaMD joins our #VirtualTumorBoard!!
Remember #TumorBoardTuesday education goes beyond Twitter - we offer 🆓 CME!!
Pick up your🏆#CME & NOW #MOC(‼️) by answering quick questions regarding a case similar to @FogacciJoao’s‼️
🔗ALL CME: integrityce.com/tbt
🔗 post rationale: bit.ly/3kcIXdv
🇧🇷🎁🇧🇷
Pick up your🏆#CME & NOW #MOC(‼️) by answering quick questions regarding a case similar to @FogacciJoao’s‼️
🔗ALL CME: integrityce.com/tbt
🔗 post rationale: bit.ly/3kcIXdv
🇧🇷🎁🇧🇷
#PostTest Q1️⃣ #CME #TumorBoardTuesday @MPishvaian
🤔Now that @FogacciJoao schooled us through updates on immunotherapy for #GastricCancer, how would you answer these 2 quick ❓
🧬 Which are potentially useful immunotherapy biomarkers in gastric cancer?
🤔Now that @FogacciJoao schooled us through updates on immunotherapy for #GastricCancer, how would you answer these 2 quick ❓
🧬 Which are potentially useful immunotherapy biomarkers in gastric cancer?
1/9 #TumorBoardTuesday #PostTest Q1️⃣ #CME
Case🎀
@doctorC369 took us on a 🛣️through metastatic #GEA. Lots of pearls🦪 here. First: two ❓...then the wrap up!
🤔These biomarkers are actionable in advanced #EsophagoGastricCancer except…
👉🏽Posttest 🔗: bit.ly/3pKtAvs
Case🎀
@doctorC369 took us on a 🛣️through metastatic #GEA. Lots of pearls🦪 here. First: two ❓...then the wrap up!
🤔These biomarkers are actionable in advanced #EsophagoGastricCancer except…
👉🏽Posttest 🔗: bit.ly/3pKtAvs
2/9 #PostTest Q2️⃣ #CME #TumorBoardTuesday
👉🏽posttest🔗: bit.ly/3pKtAvs
ALL🥇CME🔗: integrityce.com/tbt
🤔 Addition of immunotherapy to chemotherapy in the 1st line Rx of advanced #EsophagoGastricCancer significantly improves PFS and OS PDL1 CPS>1%
👉🏽posttest🔗: bit.ly/3pKtAvs
ALL🥇CME🔗: integrityce.com/tbt
🤔 Addition of immunotherapy to chemotherapy in the 1st line Rx of advanced #EsophagoGastricCancer significantly improves PFS and OS PDL1 CPS>1%
3/9 #TumorBoardTuesday
Thursday Case🎀- 12.14.2021
Lots of take🏠messages- 2 TWEETS!
We discussed metastatic #GEA
✅Chemo + XRT needed to be used fast when facing obstruction- biomarkers can wait
📣✅REMEMBER- no 5-FU bolus‼️📣
Thursday Case🎀- 12.14.2021
Lots of take🏠messages- 2 TWEETS!
We discussed metastatic #GEA
✅Chemo + XRT needed to be used fast when facing obstruction- biomarkers can wait
📣✅REMEMBER- no 5-FU bolus‼️📣
1/10 #TumorBoardTuesday
Thursday Case🎀
This week’s case: pt w #GEA not responding to FLOT w dMMR/MSI. Receives 3 doses of pembrolizumab->pCR!
💡Biomarker-based IO can be v successful, but better biomarkers needed‼️
➡️Explore wrap up below re: deploying IO in #UGI
Thursday Case🎀
This week’s case: pt w #GEA not responding to FLOT w dMMR/MSI. Receives 3 doses of pembrolizumab->pCR!
💡Biomarker-based IO can be v successful, but better biomarkers needed‼️
➡️Explore wrap up below re: deploying IO in #UGI
2/10 #TumorBoardTuesday
👉👉 Don’t forget to pick up your 🆓 #CME credit by answering 2 quick ❓
Here is the post-test 🔗: bit.ly/3EgtZeE
ALL CME 🔗: integrityce.com/tbt
👉👉 Don’t forget to pick up your 🆓 #CME credit by answering 2 quick ❓
Here is the post-test 🔗: bit.ly/3EgtZeE
ALL CME 🔗: integrityce.com/tbt
3/10 #TumorBoardTuesday
Thursday Case🎀
Take🏠messages:
We discussed #GastricCancer & immunotherapy (IO)
✅dMMR/MSI quite common- 8-22% of non-metastatic cases
✅Chemo less effective in dMMR disease, particularly 5-FU
✅High pCR with upfront IO
✅ctDNA may be a key biomarker
Thursday Case🎀
Take🏠messages:
We discussed #GastricCancer & immunotherapy (IO)
✅dMMR/MSI quite common- 8-22% of non-metastatic cases
✅Chemo less effective in dMMR disease, particularly 5-FU
✅High pCR with upfront IO
✅ctDNA may be a key biomarker
@MPishvaian @TumorBoardTues @SalemGIOncDoc @YJanjigianMD @DocCatenacci @rachnatshroff @gabe_a_brooks @sonbol_bassam @JoeChaoMD @JohnEbbenMDPhD 2/13 #TumorBoardTuesday
Starts on FLOT. C2 c/b😴, neutropenia, LFT ⬆️.
Unplanned CT with🙅🏼♂️👎response, hard to separate mass from liver capsule (not metastatic).
MDC feels risk of R1 resection, but resectable. MMR testing, complete PMS2 & MLH1 loss
Starts on FLOT. C2 c/b😴, neutropenia, LFT ⬆️.
Unplanned CT with🙅🏼♂️👎response, hard to separate mass from liver capsule (not metastatic).
MDC feels risk of R1 resection, but resectable. MMR testing, complete PMS2 & MLH1 loss
@MPishvaian @TumorBoardTues @SalemGIOncDoc @YJanjigianMD @DocCatenacci @rachnatshroff @gabe_a_brooks @sonbol_bassam @JoeChaoMD @JohnEbbenMDPhD @LFerri123 @MarkarSheraz @doctorC369
@MPishvaian @TumorBoardTues @SalemGIOncDoc @YJanjigianMD @DocCatenacci @rachnatshroff @gabe_a_brooks @sonbol_bassam @JoeChaoMD @JohnEbbenMDPhD 3/13 #TumorBoardTuesday Mini 🧑🎓 tweetorial 1⏲️
🧐 How common is dMMR in non-metastatic #GEA?
➡️ ~8% in pooled data from pIII periop and adjuvant trials
1. pubmed.ncbi.nlm.nih.gov/31513484/
2. pubmed.ncbi.nlm.nih.gov/28241187/
@FilippoPietran4 @JeeyunM @LizzySmyth1
🧐 How common is dMMR in non-metastatic #GEA?
➡️ ~8% in pooled data from pIII periop and adjuvant trials
1. pubmed.ncbi.nlm.nih.gov/31513484/
2. pubmed.ncbi.nlm.nih.gov/28241187/
@FilippoPietran4 @JeeyunM @LizzySmyth1
1/12 #TumorBoardTuesday
Thurs 10/12/21 Case🎀
@ShaalanBeg @CancerCommons present a case of #PancreaticCancer that challenges us to🤔about cell signaling & mol bio➡️better outcomes.
📚We captured as much of the chat as we could:
twitter.com/i/events/14479…
#PanCan #KRAS #OncTwitter
Thurs 10/12/21 Case🎀
@ShaalanBeg @CancerCommons present a case of #PancreaticCancer that challenges us to🤔about cell signaling & mol bio➡️better outcomes.
📚We captured as much of the chat as we could:
twitter.com/i/events/14479…
#PanCan #KRAS #OncTwitter
2/12 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages:
We discussed #PancreaticCancer & specific #KRAS mut
✅All KRAS muts aren’t ≠
✅KRAS G12R➡️⬆️autophagy
✅Autophagy= tumor can♻️cell components ➡️resistance
✅MEKi + autophagy inhib= strat for G12R
✅Repeat NGS on prog is🗝️!
Thurs Case🎀
Take🏠messages:
We discussed #PancreaticCancer & specific #KRAS mut
✅All KRAS muts aren’t ≠
✅KRAS G12R➡️⬆️autophagy
✅Autophagy= tumor can♻️cell components ➡️resistance
✅MEKi + autophagy inhib= strat for G12R
✅Repeat NGS on prog is🗝️!
3/12
#TumorBoardTuesday
Thursday Case🎀
👉👉 Don’t forget to pick up 🆓 #CME credit by answering 3 quick ❓
Here is the post-test 🔗: bit.ly/3Bzgply
ALL CME 🔗: integrityce.com/tbt
#TumorBoardTuesday
Thursday Case🎀
👉👉 Don’t forget to pick up 🆓 #CME credit by answering 3 quick ❓
Here is the post-test 🔗: bit.ly/3Bzgply
ALL CME 🔗: integrityce.com/tbt
#Deşifreiki
1-Hızlanıyoruz demiştik..
Hızlanınca, her yerden çatlama vs dağılma sesleri gelmeye başladı.
Önce yaşadıklarımıza inanamadık.
Başta doğal karşıladık.
Şimdi ise kendimizi sorguluyoruz.
Neler oluyor?
Çok acayip şeyler oluyor.
Burada önemli husus IRADE güçlü olacak.
1-Hızlanıyoruz demiştik..
Hızlanınca, her yerden çatlama vs dağılma sesleri gelmeye başladı.
Önce yaşadıklarımıza inanamadık.
Başta doğal karşıladık.
Şimdi ise kendimizi sorguluyoruz.
Neler oluyor?
Çok acayip şeyler oluyor.
Burada önemli husus IRADE güçlü olacak.
2-Düşmanın ters psikolojik harekatına karşı şöyle söyleyelim.
Satranç ve savaş 6. Boyut kabilinde devam ediyor.
Ne bu toprakları teslim edeceğiz.
Ne devletimizi yıkmalarına , bölmelerine müsade edeceğiz.
Ne de Özümüzü kaybedeceğiz.
Satranç bir savaş oyunudur.
Satranç ve savaş 6. Boyut kabilinde devam ediyor.
Ne bu toprakları teslim edeceğiz.
Ne devletimizi yıkmalarına , bölmelerine müsade edeceğiz.
Ne de Özümüzü kaybedeceğiz.
Satranç bir savaş oyunudur.
3-Görünürde Mars oluyoruz gibi ama , hep Mat ediyoruz.
Bilesiniz..
Sorun ise sizlerin FREKANS ayarlarınızı düzeltmeme..
Ve Bakar kör gibi davranışlarınızda..
Uyku halinden ayağa kalkmama..
Bu videoyu deprem öncesinden açıklamıştık.
Bilesiniz..
Sorun ise sizlerin FREKANS ayarlarınızı düzeltmeme..
Ve Bakar kör gibi davranışlarınızda..
Uyku halinden ayağa kalkmama..
Bu videoyu deprem öncesinden açıklamıştık.
Ok...Honeymoon is over & now time to dissect the exciting new data presented @ #ESMO2020 for #GEC #KN590 #CM649 #ATTRCN4 #CM577
1st, thank you to all the pts who participated!
& 2nd, congrats to all the investigators involved!
It's fantastic to have +ve studies! Lets dive deep:
1st, thank you to all the pts who participated!
& 2nd, congrats to all the investigators involved!
It's fantastic to have +ve studies! Lets dive deep:
*Caution
I think the facts are accurate - please correct if not. (seeking the truth here)
My opinions are my opinions.
~15 min read (it's complicated)
No CME offered unfortunately 😒😉
Enjoy...
I think the facts are accurate - please correct if not. (seeking the truth here)
My opinions are my opinions.
~15 min read (it's complicated)
No CME offered unfortunately 😒😉
Enjoy...
Background:
IO monotx effective in a subgroup of GEC pts in 1L+:
1. MSI-H
2. High PDL1 (cut-off at least CPS 10 22C3)
3. low tumor burden
4. PS0
5. Asian > Western pts
6. SCC > AC
7. GC > EGJ
Outside of above, most pts are better-served w chemo based on crossing #yinyang curves
IO monotx effective in a subgroup of GEC pts in 1L+:
1. MSI-H
2. High PDL1 (cut-off at least CPS 10 22C3)
3. low tumor burden
4. PS0
5. Asian > Western pts
6. SCC > AC
7. GC > EGJ
Outside of above, most pts are better-served w chemo based on crossing #yinyang curves
It will be important to look at the data closely, particularly by histology. Merck’s KEYTRUDA® (pembrolizumab) in Combination W Chemo Significantly Improved OS and PFS Compared W Chemo in 1L Metastatic Esophageal Cancer | Business Wire businesswire.com/news/home/2020…
We must recall that a ~500 pt study of the exact same regimen KN062 was recently statistically negative (HR0.85 p=0.046) in CPS>0 in adeno. Now the same regimen in KN590 N=749, in all-comers irrespective of PDL1 but including SCC, is +ve. What could be driving this difference?🤔
One of my labors of love. Appropriately online on Valentine’s Day! ❤️ Perioperative gFOLFIRINOX for #GEA with premptive iri dose reduction of hi risk UGT1A1 genotypes. ja.ma/2vCgd7T @UCCancerCenter @kturaga @SteveMaronMD with nice commentary @JoeChaoMD & @KlempnerSam.
The presentation of this poster at #ASCO2019, you can imagine, didn’t have any investors hovering around 😏.
Around 3000 BCE in eastern #Europe, a Proto-Balto-Slavic #language started to diverge from #ProtoIndoEuropean.
The #Slavic branch of the #IndoEuropean #languages began about 2,000 years later when Proto-Slavic deviated from Proto-Balto-Slavic.
[Image: commons.wikimedia.org/wiki/File:Balt…]
The #Slavic branch of the #IndoEuropean #languages began about 2,000 years later when Proto-Slavic deviated from Proto-Balto-Slavic.
[Image: commons.wikimedia.org/wiki/File:Balt…]
As the #Slavic-speaking area expanded during the first millennium CE (striped area on map), Proto-Slavic transitioned to Common Slavic. The #language underwent minor changes that occurred mostly uniformly across eastern #Europe, thereby maintaining mutual intelligibility.
Around the year 1000 CE #CommonSlavic began to split into the South, West, and East branches to which all modern #Slavic #languages belong.
Roughly 315m people speak a Slavic #language, mostly in Eastern #Europe (including the #Balkan peninsula), #CentralAsia, and #Siberia.
Roughly 315m people speak a Slavic #language, mostly in Eastern #Europe (including the #Balkan peninsula), #CentralAsia, and #Siberia.
